

Data Sheet IL-2-Luciferase Reporter (Luc) - Jurkat Cell Line Catalog # 60481

Description

Human IL-2 reporter construct is stably integrated into the genome of Jurkat T-cells. The firefly luciferase gene is controlled by a human IL-2 promoter.




Figure 1. Illustration of IL-2 promoter region with representative transcription factor binding site.

Background

Interleukin-2 (IL-2) is a key cytokine important for proliferation and differentiation of T cells into effector T cells through interaction with the IL-2 receptor.

Host Cell

Human Acute T-Cell Leukemic Cell Line (Clone E61). Suspension cells.

Format

Each vial contains $\sim 2 \times 10^6$ cells in 1 ml of 10% DMSO in FBS.

Storage

Store in liquid nitrogen immediately upon receipt.

Culture Medium

Thaw Medium 2 (BPS Cat. #60184): RPMI 1640 medium (Thermo Fisher, Cat. #A1049101) supplemented with 10% FBS (Thermo Fisher, Cat. #26140079), 1% Penicillin/Streptomycin (Hyclone #SV30010.01).

Growth Medium 2B (BPS Cat. #79530): Thaw Medium 2 (BPS Cat. #60184) supplemented with 1 mg/ml G418 (Thermo Fisher, Cat. No.11811031).

Recommended Culture conditions

Frozen Cells: Prepare a 50 ml conical tube and a T-25 culture flask with 5 ml of pre-warmed Thaw Medium 2. Quickly thaw cells in a 37°C water bath with constant and slow agitation. Clean the outside of the vial with 70% ethanol and immediately transfer the entire contents to the



conical tube with Thaw Medium 2 (**no G418**) and rock the tube gently. Centrifuge the cells at 200 x g for 3 minutes. Re-suspend the cells in 5 ml of pre-warmed Thaw Medium 2 (**no G418**) and transfer the entire content to the T25 culture flask containing Thaw Medium 2 (**no G418**). Avoid pipetting up and down, and gently rock the flask to distribute the cells. Incubate the cells in a humidified 37°C incubator with 5% CO₂. Forty-eight hours after incubation, centrifuge cells at 250 x g for 5 minutes and re-suspend to fresh Thaw Medium 2 (**no G418**). Continue to monitor growth for 2-3 days and change medium to remove dead debris. If slow cell growth occurs during resuscitation, increase FBS to 15% for the first week of culture. Switch to Growth Medium 2B (**containing G418**) after multiple cell colonies (in clumps) start to appear (indicative of healthy cell division). We recommend passing cells for 3 passages after thawing before using them in the luciferase assay.

Subculture: When cells reach ~2.5 x 10^6 cells/ml, transfer cells to a 50 ml conical tube and centrifuge cells at 200 x g for 5 minutes. Wash cells once with PBS (without Magnesium or Calcium) and re-suspend cells in 10 ml pre-warmed Growth Medium 2B; gently pipette up and down to dissociate cell clumps. Dispense cell suspension at a 1:5 to 1:10 ratio into a new T-75 flask containing pre-warmed 15-20 ml Growth Medium 2B. Incubate cells in a humidified 37°C incubator with 5% CO₂. Cells have been demonstrated to be stable for at least 15 passages; BPS recommends preparing frozen stocks so cells are not used beyond passage 20.

Mycoplasma Testing

This cell line has been screened using the MycoAlert[™] Mycoplasma Detection Kit (Cat. No. LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Cat. No. LT07-518) was used as a positive control.

Application

The IL-2-luciferase Jurkat reporter cell line is suitable for monitoring the transcription activity of IL-2 in response to stimulants, and establishing cell-based screens for inhibitors that target specific IL-2 stimulating molecules. This reporter cell line has been tested and validated by BPS using stimuli including a combination of phorbol 12-myristate 13-acetate (PMA) with ionomycin (**Figure 2**), anti-human CD3 antibody (**Figure 3**) and TCR activator / CHO-K1 cell line (**Figure 4**). This cell line is sensitive to stimuli at 2- 4 x 10⁵ cells/ ml in 100 µl of serum free medium in a 96 well plate. For optimal sensitivity, BPS recommends using the provided protocols.

Application References

- Weaver JR *et.al.* (2007) Characterization of the sequence and architectural constraints of the regulatory and core regions of the human interleukin-2 promoter. *Mol. Immunol.* 44: 2813-2819.
- 2. Hughes CCW and Pober JS (1996) Transcriptional Regulation of the Interleukin-2 Gene in Normal Human Peripheral Blood T Cells. *J. Biol. Chem.* **271**: 5369-5377.



Assay Protocol

A) Analysis of IL-2 Jurkat reporter activity in response to PMA/ionomycin

- In a white opaque 96- well plate, seed cells at 2 4x10⁴ cells/well (100 μl per well) in serum free RPMI medium. Cells should be growing at log phase at time of seeding.
- Prepare fresh working solution of PMA (Fisher, Cat # BP685-1) at 10 ug/ml (from 1mg/ml stock in DMSO) and ionomycin (Fisher, Cat # BP25271) at 5 μg/ml (from 1 mg/ml stock in DMSO) in PBS.
- Immediately treat 100 μl of cells with 10 μl of working solution of PMA and ionomycin for 24 hours at 37°C with 5% CO₂ (Figure 2). We used a starting concentration at 1 μg /ml for PMA and did a 3-fold serial dilution in PBS containing a constant level of ionomycin at 500 ng/ml (final concentration).
- 4. Add ONE-Step[™] Luciferase Assay System (BPS Bioscience, Cat. No. 60690) to each well, according to recommended protocol.
- 5. Read luminescence using a luminometer. Normalize luminescence to wells that contain only medium to obtain the Relative Luminescence Units (RLUs).




Figure 2. Response to PMA and Ionomycin Stimulation.

IL-2 Jurkat reporter cells were seeded at 3 x10⁴ cells/well (100 μl per well) in serum free RPMI medium and treated with ionomycin and PMA. Error bar = standard deviation (SD), n=3. OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE. To place your order, please contact us by Phone **1.858.829.3082** Fax **1.858.481.8694** Or you can Email us at: <u>info@bpsbioscience.com</u> Please visit our website at: <u>www.bpsbioscience.com</u>



B) Analysis of IL-2 Jurkat reporter activity in response to anti-CD3 antibody

- In a white opaque 96- well plate, seed cells at 1 4x10⁴ cells/well (100 μl per well) in serum free RPMI medium overnight. Cells should be growing at log phase at time of seeding; do not use cells that have grown beyond 5 x 10⁵ cells/ml in a T25 flask. Passage cells a day prior to seeding if cells are at high density.
- The next day, immediately treat cells with anti-CD3 antibody for 24 hours at 37°C with 5% CO₂ (Figure 3). We used a starting concentration at 10 µg/ml, with subsequent three fold serial dilutions.
- 3. Add ONE-Step[™] Luciferase Assay System (BPS Bioscience, Cat. No. 60690) to each well, according to recommended protocol.
- 4. Read luminescence using a luminometer. Normalize luminescence to wells that contain only medium to obtain the Relative Luminescence Units (RLUs).




Figure 3. Response to Anti-human CD3 Antibody.

IL-2 Jurkat reporter cells were seeded at 1 x10⁴ cells/well (100 μ l per well) in serum free RPMI. Cells were treated with LEAFTM Purified anti-human CD3 antibody (clone OKT3, Biolegend Cat. No. 317325; BPS Cat. No.71274) over the indicated concentration range for 24 hours at 37°C with 5% CO₂. Error bar = standard deviation (SD), n=3.



- C) Analysis of IL-2 Jurkat reporter activity in response to TCR-Activator CHO Recombinant Cells.
- In a white opaque 96- well plate, seed 1-4 x 10⁴ TCR-Activator CHO cells in complete medium (10% FBS in F-12). Gently shake the plate to ensure cells are evenly distributed. Cells should be 60-80% confluent the next day. Do not use cells that are >90% confluent.
- 2. The next day, remove medium from each well, and add 2 4 x 10⁴ IL-2 Jurkat reporter cells (100 μl per well) in serum free RPMI for ~24 hours at 37°C with 5% CO₂ (**Figure 4**).
- 3. Add ONE-Step[™] Luciferase Assay System (BPS Bioscience, Cat. No. 60690) to each well, according to recommended protocol.
- 4. Read luminescence using a luminometer. Normalize luminescence to wells that contain only medium to obtain the Relative Luminescence Units (RLUs).




Figure 4. Response to TCR Activator - CHO Recombinant Cells.

4 x 10^4 TCR Activator - CHO Recombinant Cells (BPS Cat. No. 60539) or naïve CHO cells were co-cultured with IL-2 reporter Jurkat or naïve Jurkat cells. Error bar = standard deviation (SD), n=9.






Figure 5. Response to Human T-Activator CD3/CD28 Dynabeads

IL-2 Jurkat cells were seeded on a white opaque 96-well plate at 2 x 10^4 cells/well (100 µl per well) in serum-free hybridoma medium. Cells were treated with anti-human CD3/CD28 Dynabeads (Thermo Fisher Cat. No. 1132D) at 4 µl per well for ~24 hours at 37°C with 5% CO₂, and compared to untreated cells. Error bar = standard deviation (SD), n=3.

Related Products

Product	<u>Cat. #</u>	<u>Size</u>
ONE-Step [™] Luciferase Assay System	60690-1	10 ml
ONE-Step [™] Luciferase Assay System	60690-2	100 ml
Jurkat Cell Thawing Medium	60184	100 ml
TCR Activator/ CHO Cell Line	60539	2 vials
NFAT- Luc Jurkat Cell Line	60621	2 vials
Anti-CD3 Antibody	71274-2	100 ug



License Disclosure

Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS products to your laboratory. BPS does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact sales@bpsbioscience.com for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego.